Synta Pharmaceuticals (SNTA) Release: Interim Results of the GALAXY-1 Trial to be Presented at Best of American Society of Clinical Oncology
8/7/2013 10:09:02 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that the results from an interim survival analysis of the GALAXY-1 trial will be presented at this year’s Best of ASCO Meetings in Chicago, Los Angeles, and Boston. GALAXY-1 is a global, randomized Phase 2b/3 study designed to evaluate the efficacy and safety of the Company’s lead drug candidate, ganetespib, as second-line treatment for patients with advanced non-small cell lung adenocarcinoma.
Help employers find you! Check out all the jobs and post your resume.